SCLX Scilex Holding Co
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1820190 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-28.5%
TTM net income YoY-473.7%
TTM EPS YoY-2,120.1%
Revenue 3-yr CAGR-12.0%
Net income 3-yr CAGR—
Margins
Gross margin161.1%
Operating margin-1,136.4%
Net margin-1,469.8%
FCF margin—
EBITDA margin-1,119.8%
Returns
ROE—
ROA-275.4%
ROIC (approx.)—
Asset turnover0.19x
Leverage & solvency
Liabilities / assets222.5%
Debt / equity—
Current ratio0.07x
Interest coverage-22.20x
Cash quality & payout
Operating cash flow / net income0.04x
Accruals ratio-265.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.64M | $8.61M | $4.79M | $10.56M | $9.90M | $5.00M | $14.90M | $14.44M |
| Cost of revenue | $3.68M | $4.45M | $2.61M | $3.33M | $3.27M | $1.38M | $4.69M | $3.77M |
| Gross profit | $15.80M | $25.70M | $2.18M | $7.23M | $39.50M | $17.70M | $10.21M | $10.67M |
| R&D expense | $3.34M | $3.21M | $8.17M | $3.90M | $6.19M | $2.46M | $2.18M | $2.35M |
| SG&A expense | $27.96M | $31.03M | $30.16M | $188.82M | $19.84M | $28.06M | $35.41M | $29.73M |
| Operating income | -$29.42M | -$32.17M | -$111.09M | -$186.51M | -$20.51M | -$27.90M | -$28.38M | -$19.92M |
| Interest expense | $6.10M | $3.78M | $3.50M | $2.80M | $2.68M | $2.48M | $285,000 | $576,000 |
| Pretax income | -$114.98M | -$45.65M | -$46.10M | -$257.82M | -$44.03M | -$26.08M | -$6.46M | -$4.39M |
| Income tax | $7,000 | — | $6,000 | $1,000 | $19,000 | — | -$1,000 | $0 |
| Net income | -$114.99M | -$45.65M | -$46.10M | -$257.82M | -$44.05M | -$26.08M | -$6.46M | -$4.39M |
| EBITDA | -$28.62M | -$29.30M | -$109.50M | -$186.51M | -$20.50M | -$26.89M | -$27.37M | -$19.91M |
| EPS (basic) | -16.65 | -6.28 | — | -22.17 | -7.42 | -2.26 | — | -0.58 |
| EPS (diluted) | -16.65 | -6.28 | — | -22.17 | -7.42 | -2.26 | — | -0.58 |
| Weighted avg. shares (diluted) | 6.89M | 6.89M | — | 11,604 | 11.60M | 11.56M | — | 7,557 |
| Banking | ||||||||
| Provision for credit losses | $73,000 | $800,000 | — | $0 | $0 | $0 | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $566,000 | $3.35M | $4.96M | $878,000 | $4.10M | $5.80M | $3.27M | $8.12M |
| Receivables | $6.44M | $10.65M | $15.24M | $11.94M | $16.77M | $10.62M | $26.44M | $31.58M |
| Inventory | $4.17M | $4.53M | $4.79M | $1.08M | $2.52M | $3.02M | $2.44M | $2.40M |
| Current assets | $36.23M | $41.97M | $38.36M | $16.49M | $33.67M | $28.70M | $41.55M | $39.85M |
| PP&E, net | $12.77M | $13.38M | $13.60M | $703,000 | $705,000 | $707,000 | $708,000 | $711,000 |
| Goodwill | $13.48M | $13.48M | $13.48M | $13.48M | $13.48M | $13.48M | $13.48M | $13.48M |
| Intangibles | $57.61M | $59.81M | $59.09M | $30.42M | $31.44M | $31.45M | $32.45M | $33.45M |
| Total assets | $253.56M | $293.63M | $364.98M | $275.88M | $83.75M | $78.98M | $92.95M | $100.43M |
| Current liabilities | $512.24M | $501.75M | $483.65M | $358.95M | $305.93M | $275.74M | $259.63M | $281.54M |
| Short-term debt | $80.81M | $80.78M | $83.26M | $45.67M | $39.87M | $39.44M | $34.88M | $84.64M |
| Total liabilities | $564.05M | $547.71M | $576.73M | $455.60M | $332.74M | $290.46M | $285.59M | $311.75M |
| Shareholders' equity | -$308.32M | -$249.22M | -$207.78M | -$176.94M | -$248.99M | -$211.48M | -$192.64M | -$211.32M |
| Shares outstanding | 7.03M | 8.49M | 7.03M | 5.95M | 5.50M | 5.49M | 5.24M | 131.72M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.74M | -$1.11M | -$17.47M | $8.23M | $7.05M | $6.01M | $2.53M | $5.11M |
| Capital expenditure | — | — | — | — | — | — | $0 | $0 |
| Free cash flow | — | — | — | — | — | — | $2.53M | $5.11M |
| Investing cash flow | $8.45M | -$9.16M | $4.78M | -$152,000 | -$153,000 | -$395,000 | -$195,000 | -$2.18M |
| Financing cash flow | -$4.48M | $9.14M | $17.52M | -$11.30M | -$8.60M | -$3.08M | -$7.18M | -$4.48M |
| Depreciation & amortization | $800,000 | $2.87M | $1.59M | $2,000 | $2,000 | $1.00M | $1.00M | $4,000 |
| Stock-based compensation | $3.60M | $3.63M | $5.64M | $3.26M | $3.28M | $3.31M | $4.80M | $3.71M |
Free plan shows the latest 8 periods; Pro shows all 24 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.